Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20211122006506/en/Qurient-Announces-Collaboration-Agreement-with-MSD-to-Evaluate-Selective-Triple-Inhibitor-Q702-in-Combination-With-KEYTRUDA%C2%AE-pembrolizumab

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202111237480i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202110146850i

Article Source : 한국경제
Link : https://www.hankyung.com/finance/article/202107297778i

Article Source : 한국경제
Link : https://www.hankyung.com/finance/article/202104122123i

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2021032215043796600

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202101263518i

Article Source : Business Wire
Link : https://www.businesswire.com/news/home/20210126005764/en/Qurient-Enrolls-First-Patient-in-Q702-U.S.-Phase-1-Study

Article Source : 머니투데이
Link : https://news.mt.co.kr/mtview.php?no=2021011411094667202

Article Source : Korea Biomedical Review
Link : http://www.koreabiomed.com/news/articleView.html?idxno=10169

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202101117023i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202012043320i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202010131248i

Article Source : 한국경제
Link : https://www.hankyung.com/it/article/202009248714i